MDxHealth SA

Good day and welcome to the MDX Health third quarter 2024 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To try your question, please press star then two. Please note this event is being recorded. Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factors section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20F. I now would like to send the conference over to Michael McGarrity, Chief Executive Officer. Please go ahead.

Thanks, Keith. And thank you all for joining us for our third quarter 2024 earnings conference call for MDX Health. With me today is Ron Kalfas, Chief Financial Officer. The third quarter marked another period of solid performance for our company, as demonstrated by year-over-year revenue growth of 21%, or when adjusted for select revenue backlog in the third quarter of last year following our Medicare coverage, an effective year-over-year revenue growth rate of 27%. Based on consistent commercial execution and operating discipline, we believe that our growing leadership position in the urology precision diagnostics will position us to generate strong and sustainable revenue growth of at least 20%. And we are confident we will meet or exceed that growth rate for the full year 2025. Before I hand it over to Ron for a review of our financial and operating results, a few comments on our focus and execution. We reported third quarter revenue of $23.3 million, an increase of 21% over the prior year period. Once again, we are seeing consistently strong performance across our two main levers of revenue growth, with our sales team driving unit adoption and our market access team continuing to drive coverage, which shows up in our ASP.

Both levers are working.